Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.
This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on Cerulean Pharma Inc. as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for CERU’s status as a solid momentum stock below:
Short Term Price Change for Cerulean Pharma
A great place to look for finding momentum stocks is by inspecting short term price activity. This can help to reflect the current interest in a stock and if buyers or sellers have the upper hand right now. It is especially useful to compare it to the industry as this can help investors pinpoint the top companies in a particular area.
With a one week price change of 9.3% compared to an industry average of -1.1%, CERU is certainly well-positioned in this regard. The stock is also looking quite well from a longer time frame too, as the four week price change compares favorably with the industry at large as well.
Fiscal Year EPS Estimate Change for CERU
In addition to price performance, it is also important to take a look at earnings estimate changes for the full year. This can show if CERU is poised to make a run based on fundamentals, or if the company is simply moving on speculation.
Over the past month, the full year earnings estimate for CERU has risen by 6.8%. On its own this is impressive, but consider that it also beats the industry average of 0 too. The trend is undeniably in Cerulean Pharma’s favor right now, and it suggests that the momentum might be long lasting for this stock.
CERU Earnings Estimate Revisions Moving in the Right Direction
While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with CERU as of late too.
Over the past two months, one earnings estimate has gone higher compared to none lower for the full year. This has helped to boost the consensus estimate as two months ago CERU was expected to post a loss of $1.66/share for the full year, though today it looks to have a loss of $1.63 for the full year now, representing a solid increase which is something that should definitely be welcomed news to would-be investors.
Bottom Line
Given these factors, investors shouldn’t be surprised to note that we have CERU as a security with a Zacks Rank #2 (Buy) and a Momentum Score of ‘B’. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep CERU on your short list as this looks be a stock that is very well-positioned to soar in the near term.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Image: Bigstock
3 Reasons Why Cerulean Pharma (CERU) is a Great Momentum Stock
Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.
This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on Cerulean Pharma Inc. as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for CERU’s status as a solid momentum stock below:
Short Term Price Change for Cerulean Pharma
A great place to look for finding momentum stocks is by inspecting short term price activity. This can help to reflect the current interest in a stock and if buyers or sellers have the upper hand right now. It is especially useful to compare it to the industry as this can help investors pinpoint the top companies in a particular area.
With a one week price change of 9.3% compared to an industry average of -1.1%, CERU is certainly well-positioned in this regard. The stock is also looking quite well from a longer time frame too, as the four week price change compares favorably with the industry at large as well.
Fiscal Year EPS Estimate Change for CERU
In addition to price performance, it is also important to take a look at earnings estimate changes for the full year. This can show if CERU is poised to make a run based on fundamentals, or if the company is simply moving on speculation.
Over the past month, the full year earnings estimate for CERU has risen by 6.8%. On its own this is impressive, but consider that it also beats the industry average of 0 too. The trend is undeniably in Cerulean Pharma’s favor right now, and it suggests that the momentum might be long lasting for this stock.
CERU Earnings Estimate Revisions Moving in the Right Direction
While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with CERU as of late too.
Cerulean Pharma Inc. Price and Consensus
Cerulean Pharma Inc. Price and Consensus | Cerulean Pharma Inc. Quote
Over the past two months, one earnings estimate has gone higher compared to none lower for the full year. This has helped to boost the consensus estimate as two months ago CERU was expected to post a loss of $1.66/share for the full year, though today it looks to have a loss of $1.63 for the full year now, representing a solid increase which is something that should definitely be welcomed news to would-be investors.
Bottom Line
Given these factors, investors shouldn’t be surprised to note that we have CERU as a security with a Zacks Rank #2 (Buy) and a Momentum Score of ‘B’. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep CERU on your short list as this looks be a stock that is very well-positioned to soar in the near term.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>